Recently, a large subgroup analysis of KRAS mutant NSCLC patients treated with nivolumab within the Italian Expanded Access Program clearly showed that nivolumab did not improve ORR, neither PFS nor OS in KRAS mutant respect to KRAS wild type patients (ORR, 20% vs. 17%; median PFS, 4 vs. 3 months; median OS, 11.2 vs. 10 months), although the 3-months PFS rate was significantly longer in KRAS mutant than KRAS wild type patients (53% vs. 42%) [154]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.